Unlock the power of real-world evidence (RWE) in drug development with protocol-based disease registries. These clinically rich sources of real-world data (RWD) are purpose-built for research, offering valuable insights into treatment patterns, effectiveness outcomes and the natural history of diseases.
In this webinar, a panel of industry leaders explore:
- The types of RWD that can be collected in registries
- How RWD can be used to conduct nested, customized registry-based studies
- How to ensure data are collected consistently across patients, practice settings, geography and time
- How to determine if and what kind of registry you require
- What regulators say about using RWD from registries to inform their decision making
- Whether registry data can be used and linked to other data sources
- How to get from data to actionable insights
Speakers:
- Peter Wahl, MLA, MS, ScD, vice president & global head of scientific affairs, CorEvitas, part of the PPD clinical research business of Thermo Fisher Scientific
- Heather Litman, Ph.D., vice president of biostatistics, CorEvitas, part of the PPD clinical research business of Thermo Fisher Scientific
- Nahila Justo, D., MBA, executive director of real-world evidence integrated solutions, Evidera, part of the PPD clinical research business of Thermo Fisher Scientific
- Javier Cid, D., DrPH, MBA, senior research scientist, data analytics, Evidera, part of the PPD clinical research business of Thermo Fisher Scientific
- Delphine Saragoussi, D., MScPH, executive director, real-world evidence, epidemiology and scientific affairs, Evidera, part of the PPD clinical research business of Thermo Fisher Scientific
Complete the form to watch the webinar.